Company Overview and News
TORONTO, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Amarillo Gold Corporation (“Amarillo” or the “Company”) (TSX.V: AGC) (OTCQB: AGCBF) wishes to announce that it has granted 1,400,000 incentive stock options to directors and officers at a price of $0.23 with a 5 year term expiring on September 17, 2023, in accordance with TSX Venture Exchange policies.
TORONTO, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Amarillo Gold Corporation (“Amarillo” or the “Company”) (TSX.V: AGC) (OTCQB: AGCBF) is pleased to announce that it has filed on SEDAR (www.sedar.com) the Pre-Feasibility Study update on the Company’s flagship Mara Rosa Project. The highlights of this updated study titled “Technical Update on the Posse Gold Project, Brazil, September 2018” were reported in our press release on September 12, 2018.
TORONTO, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Amarillo Gold Corporation (“Amarillo” or the “Company”) (TSX.V: AGC) (OTCQB: AGCBF) is pleased to announce results of the updated Pre-Feasibility Study (“2018 PFS”) for the Posse gold deposit at its 100% owned Mara Rosa Project (the “Project”).
TORONTO, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Amarillo Gold Corporation (“Amarillo” or the “Company”) (TSX.V:AGC; OTCQB:AGCBF) today announces its financial results for the second quarter (“Q2”) ended June 30, 2018. This press release should be read in conjunction with the Company’s condensed interim consolidated financial statements and Management’s Discussion & Analysis (“MD&A”) for the three and six months ended June 30, 2018, available on the Company’s website at www.
On Aug 21, we issued an updated research report on Royal Gold, Inc. (RGLD - Free Report) . The company is poised to gain from improved production and progress in new mines. Its focus on acquisitions and strong cash flow position also bode well. However, inadequate water supplies and lower processing rates at Mount Milligan might impede the company’s near-term growth. Let’s illustrate the factors in detail.
AGCBF RGLD CTGO AGC GSS GG CE RGL GSC
TORONTO, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Amarillo Gold Corporation (“Amarillo” or the “Company”) (TSX.V:AGC) is pleased to report that it has completed six previously-announced shares for debt transactions (the “Shares for Debt Transactions”) whereby the Company issued an aggregate of 4,177,888 common shares (“Common Shares”) at a deemed price of $0.28 per share in settlement of CAD$1.2M in payables owing to certain arm’s length and non-arm’s length parties.
TORONTO, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Amarillo Gold Corporation (“Amarillo” or the “Company”) (TSX.V:AGC) today announces that its common shares have been approved for trading on the OTCQB® Venture Market in the United States under the symbol AGCBF. The Company’s common shares will continue to trade under the symbol AGC on the TSX Venture Exchange. There is no action required by current shareholders as a result of this change.
TORONTO, July 27, 2018 (GLOBE NEWSWIRE) -- Amarillo Gold Corporation (“Amarillo” or the “Company”) (TSX.V:AGC) today announces the full repayment of the gold linked credit facility (the “Gold Loan”) for USD$8.5M through a combination of USD$7.4M in cash and USD$1.1M in new equity. The Company’s intention to repay the Gold Loan was previously announced in the Company’s news release dated July 24, 2018.
2018-07-03 seekingalpha - 1
Here's a monthly recap of the top news in the gold mining sector, including acquisitions and takeover announcements, financial results and other relevant updates, to keep readers up-to-date on news in the sector. Here's my update for May, in case you missed it.
AGCBF RIO RIO YRI KGI.DB CG CAGDF RTPPF FPC AUY OR RTNTF FPRGF SEMFF KL WPM SAND SSL SDDXF KGI OKSWF KGI.DB.A SNXZF RGLD AGC RIO OSKGF RGL
TORONTO, July 03, 2018 (GLOBE NEWSWIRE) -- Amarillo Gold Corporation (“Amarillo” or the “Company”) (TSX.V:AGC) is pleased to report that it has completed the previously-announced sale of a perpetual 1.75% Net Smelter Return Royalty (the “Royalty”) on the Mara Rosa gold project (the “Mara Rosa Project”) to RG Royalties, LLC, a wholly-owned subsidiary of Royal Gold, Inc. (NASDAQ:RGLD) (“Royal Gold”), for USD $10.
AGCBF RGLD AGC RGL
TORONTO, June 29, 2018 (GLOBE NEWSWIRE) -- Amarillo Gold Corporation (“Amarillo” or the “Company”) (TSX.V:AGC) today announces the entry into an agreement for sale of a perpetual 1.75% Net Smelter Return Royalty on the Mara Rosa gold project (the “Royalty Agreement”) to RG Royalties, LLC, a wholly-owned subsidiary of Royal Gold, Inc. (NASDAQ:RGLD) (“Royal Gold”), for USD $10.8 million (approximately CAD$14.
AGCBF RGLD AGC RGL
TORONTO, ON / ACCESSWIRE / June 15, 2018 / Amarillo Gold Corporation (TSXV: AGC) ("Amarillo" or the "Company") today announces that the Company will be presenting at the MicroCap Conference on June 21st in Toronto and at the John Tumazos Conference in New Jersey June 28th, 2018.
TORONTO, June 13, 2018 (GLOBE NEWSWIRE) -- Amarillo Gold Corporation (“Amarillo” or the “Company”) (TSX.V:AGC) previously announced on May 23, 2018 that it had commenced a 10,000m drill program on its flagship Mara Rosa Project. The assay results reported in Table 1 below are from four geotechnical holes drilled in 2011, but only now assayed as part of this new campaign.
TORONTO, June 11, 2018 (GLOBE NEWSWIRE) -- Amarillo Gold Corporation (“Amarillo” or the “Company”) (TSX.V:AGC) is pleased to announce that Marc Ducharme has been appointed Chief Exploration Geologist. Mr. Ducharme is a geologist with over thirty years of experience in the minerals industry, managing and conducting exploration programs from grass roots through to advanced stage exploration and feasibility stage projects.
AGCBF AGC WDO WDOFF
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to TSXV:AGC / Amarillo Gold Corp. on message board site Silicon Investor.